Myocardial regeneration by targeting to microRNA
Project/Area Number |
23591070
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Circulatory organs internal medicine
|
Research Institution | Kansai Medical University |
Principal Investigator |
OTANI Hajime 関西医科大学, 医学部, 准教授 (60168979)
|
Co-Investigator(Kenkyū-buntansha) |
IWASAKI Masayoshi 関西医科大学, 医学部, 講師 (30548706)
|
Co-Investigator(Renkei-kenkyūsha) |
TABATA Yasuhiko 京都大学, 再生医科学研究所, 教授 (50211371)
|
Project Period (FY) |
2011 – 2013
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2012: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | 心筋再生 / 心筋再生医療 / マイクロRNA |
Research Abstract |
We investigated whether controlled release of antagomir designed to inhibit microRNA-92a leads to enhanced blood vessel growth and functional recovery after myocardial infarction (MI) in rats. There was no difference in LV wall motion between rats with the antagomir-92a patch and the patch alone 1 hour after MI. However, myocardial thinning was inhibited, and LV wall motion was improved 3 days after MI in rats with the antagomir-92a patch. Myocardial fibrosis was reduced by the antagomir-92a patch 14 days after MI. Angiogenesis within the infarct area was increased by the antagomir-92a patch associated with enhanced cardiomyogenesis. The patch alone or the patch impregnated with antagomir-Co had no effect on LV wall motion, myocardial fibrosis, angiogenesis and cardiomyogenesis after MI. These results suggest that controlled release of antagomir-92a using gelatin hydrogel microspheres-incorporated patch is an effective tool for cardiac regeneration therapy after MI.
|
Report
(4 results)
Research Products
(9 results)